TET Therapeutics

Engineering nature's solution to brain repair

Every year, millions of people suffer traumatic brain injuries (TBIs). Current cell therapies that show promise require direct surgical injection into the brain: costly, invasive, and inaccessible to most patients.

Nature already solved this problem. During pregnancy, fetal cells cross the blood-brain barrier and home to sites of maternal brain injury — repairing damage without surgery.

TET Therapeutics is engineering that biology into an IV-deliverable cell therapy platform, eliminating the need for brain surgery entirely.

What is TET?

IV Delivery

No brain surgery required

IV Delivery

No brain surgery required

Nature's Blueprint

Engineering a validated biological phenomenon

Nature's Blueprint

Engineering a validated biological phenomenon

Scalable Platform

Built for broad patient access and distributed manufacturing

Scalable Platform

Built for broad patient access and distributed manufacturing

TBI First

Initial indication with clear unmet need and path to approval

TBI First

Initial indication with clear unmet need and path to approval

Longevity Platform

Long-term vision: gradually replacing damaged neural circuitry over time

Longevity Platform

Long-term vision: gradually replacing damaged neural circuitry over time

Cost Reduction

Saves up to $260K per patient vs. surgical delivery

Cost Reduction

Saves up to $260K per patient vs. surgical delivery

Meet the Team

Amit Tal

Founder

Benjamin Wang, PhD

Scientific Advisor

[Coming Soon]

This could be you!

[Coming Soon]

This could be you!

[Coming Soon]

This could be you!

Amit Tal

Founder

Help us build TET Tx

We're seeking collaborators, advisors, and early-stage funding. Let's talk.

Help us build TET Tx

We're seeking collaborators, advisors, and early-stage funding. Let's talk.

Help us build TET Tx

We're seeking collaborators, advisors, and early-stage funding. Let's talk.

Help us build TET Tx

We're seeking collaborators, advisors, and early-stage funding. Let's talk.